2011
DOI: 10.1172/jci41695
|View full text |Cite
|
Sign up to set email alerts
|

Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
181
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 121 publications
(191 citation statements)
references
References 48 publications
9
181
0
Order By: Relevance
“…42,43 Recent studies indicated that BH3-mimetics can be used to treat nonlymphoid cancers but mostly in combination with oestrogen antagonists, proteasome inhibitors, specific PI3K-mTOR inhibitors or chemotherapy. 24,[44][45][46][47][48][49] As previous findings from our laboratory demonstrated that E-cadherin-negative lobular breast cancer depends on p120-catenin-mediated activation of RhoA, Rock and subsequent actomyosin contraction, 26 we anticipate that dual inhibition of these pathways might be successful in E-cadherin-negative cancers that are not driven by oncogenic activation of GFR pathways. Although we do not yet know whether RhoA-Rock signals converge onto the GFR-AKT-FOXO axis in the regulation of anoikis resistance, the fact that FOXO expression had no effect on survival of B-RAF/KRAS-mutated MDA-MB-231 cells seems to be in line with this assumption.…”
Section: Discussionmentioning
confidence: 83%
See 3 more Smart Citations
“…42,43 Recent studies indicated that BH3-mimetics can be used to treat nonlymphoid cancers but mostly in combination with oestrogen antagonists, proteasome inhibitors, specific PI3K-mTOR inhibitors or chemotherapy. 24,[44][45][46][47][48][49] As previous findings from our laboratory demonstrated that E-cadherin-negative lobular breast cancer depends on p120-catenin-mediated activation of RhoA, Rock and subsequent actomyosin contraction, 26 we anticipate that dual inhibition of these pathways might be successful in E-cadherin-negative cancers that are not driven by oncogenic activation of GFR pathways. Although we do not yet know whether RhoA-Rock signals converge onto the GFR-AKT-FOXO axis in the regulation of anoikis resistance, the fact that FOXO expression had no effect on survival of B-RAF/KRAS-mutated MDA-MB-231 cells seems to be in line with this assumption.…”
Section: Discussionmentioning
confidence: 83%
“…Under these conditions, the non-metastatic mouse mammary carcinoma cell line Trp53 Δ/Δ -4 and human MCF7 underwent anoikis as previously demonstrated. 20,26 In contrast, mouse and human E-cadherin-negative mILC1 and MDA-MB-231 cells were anoikis resistant (Figures 1a and b).…”
Section: Resultsmentioning
confidence: 96%
See 2 more Smart Citations
“…Alternatively, cytosolic p120catenin may activate Rho by inhibiting the antagonist of Rho/ROCK signalling Myosin phosphatase Rho-interacting protein (Mrip), in an invasive lobular carcinoma mouse model [110] (figure 4). Activation of Rho and ROCK signalling by cytosolic p120catenin can influence cell migration and invasion, and promote anchorage independent survival of Ecadherin-deficient cancer cells [110]. p120catenin can also act downstream of Src and Rac1 to suppress the RhoA-ROCK signalling pathway, highlighting the role of p120catenin in the crucial interplay between Rac and Rho signalling.…”
Section: (B) Cytosolic P120catenin Interacts With and Modulates Rho-gmentioning
confidence: 99%